Drug Approval | December 27, 2025
Chugai’s Tecentriq gets green light in Japan for hard-to-treat Thymic Carcinoma
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
The drug had previously received orphan drug designation for this rare cancer on March 31, 2025
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
Adverse events were consistent with valbenazine’s established safety profile
Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities
The study focused on patients without actionable genomic alterations whose disease had progressed after prior immunotherapy and platinum-based chemotherapy
The company also reported significant progress toward its internally defined Sustainable Development Goals
The company along with its subsidiaries has overall bed capacity of 8800+ beds as on 30th September, 2025
The pharma company will donate more than seven tons of its active pharmaceutical ingredient (API) to bolster the American supply chain
Subscribe To Our Newsletter & Stay Updated
